Discontinued — last reported Q4 '17
Non-Current Assets
Indefinite-Lived Research and Development Assets
Gilead Sciences Indefinite-Lived Research and Development Assets remained flat by 0.0% to $2.70B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.6%, from $2.89B to $2.70B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017
How to read this metric
An increase indicates active investment in future technology, while a decrease may signal project completion or impairment.
Detailed definition
These are acquired in-process research and development (IPR&D) projects that have not yet reached technological feasibil...
Peer comparison
Common in technology and pharmaceutical sectors following M&A activity.
Metric ID:
indefinite_lived_rd_assetsHistorical Data
8 periods
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $7.07B | $4.64B | $4.64B | $2.89B | $2.89B | $2.89B | $2.70B | $2.70B |
| QoQ Change | — | -34.4% | +0.0% | -37.7% | +0.0% | +0.0% | -6.6% | +0.0% |
| YoY Change | — | — | — | — | -59.1% | -37.7% | -41.8% | -6.6% |
Range$2.70B – $7.07B
CAGR-42.3%
Avg YoY Growth-36.3%
Median YoY Growth-39.8%
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's indefinite-lived research and development assets?
- Gilead Sciences (GILD) reported indefinite-lived research and development assets of $2.70B in Q3 2025.
- How has Gilead Sciences's indefinite-lived research and development assets changed year-over-year?
- Gilead Sciences's indefinite-lived research and development assets decreased by 6.6% year-over-year, from $2.89B to $2.70B.
- What does indefinite-lived research and development assets mean?
- The value of research projects acquired from other companies that are still in progress.